Publications by authors named "Michael Engwall"

Claim this Profile
C
Corrigendum to "Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As" [J. Pharmacol. Toxicol. Methods 123 (2023) 107270].
Eric I Rossman, Todd A Wisialowski, Hugo M Vargas, Jean-Pierre Valentin, Michael G Rolf, Michael J Engwall

J Pharmacol Toxicol Methods· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.
Eric I Rossman, Todd A Wisialowski, Hugo M Vargas, Jean-Pierre Valentin, Michael G Rolf, Michael J Engwall

J Pharmacol Toxicol Methods· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of levocetirizine in beagle dog and cynomolgus monkey telemetry assays: Defining the no QTc effect profile by timepoint and concentration-QTc analysis.
Michael J Engwall, Joel Baublits, Fiona A Chandra, Zack W Jones, Jan Wahlstrom

Clin Transl Sci· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The in vivo QTc core assay: An evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies.
Joel Baublits, Hugo M Vargas, Michael J Engwall

J Pharmacol Toxicol Methods· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis.
Ray W Chui, Joel Baublits, Fiona A Chandra, Zack W Jones, Michael J Engwall

Clin Transl Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "The in vivo QTc core assay: An evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies" [Journal of Pharmacological and Toxicological Methods 109 (2021) 107067].
Joel Baublits, Hugo M Vargas, Michael J Engwall

J Pharmacol Toxicol Methods· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Hugo M Vargas, Michael G Rolf, Todd A Wisialowski, William Achanzar, Anthony Bahinski, Michael J Engwall

Clin Pharmacol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of Repeat-Dose Doxorubicin on Cardiovascular Functional Endpoints and Biomarkers in the Telemetry-Equipped Cynomolgus Monkey.
Michael J Engwall, Nancy Everds, James R Turk, Hugo M Vargas

Front Cardiovasc Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
James R Turk, Aimee M Deaton, Jun Yin, Marina Stolina, Melanie Felx, Michael Engwall

Regul Toxicol Pharmacol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro.
Hamid R Amouzadeh, Isaiah Dimery, Jonathan Werner, Gataree Ngarmchamnanrith, Michael J Engwall

Transl Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for an , Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.
Brian D Guth, Michael Engwall, Sandy Eldridge, C Michael Foley, Liang Guo

Front Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for an , Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes.
Alexandre J S Ribeiro, Brian D Guth, Michael Engwall, Sandy Eldridge, C Michael Foley

Front Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evaluation of endpoint variability and implications for study statistical power and sample size in conscious instrumented dogs.
Alan Y Chiang, Brian D Guth, Michael K Pugsley, C Michael Foley, Jennifer M Doyle, Michael J Engwall

J Pharmacol Toxicol Methods· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of the utility of LVdP/dt, QA interval, LVdP/dt and Tau as indicators of drug-induced changes in contractility and lusitropy in dogs.
Michael K Pugsley, Brian Guth, Alan Y Chiang, Jennifer M Doyle, Michael Engwall

J Pharmacol Toxicol Methods· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium.
Brian D Guth, Alan Y Chiang, Jennifer Doyle, Michael J Engwall, Jean-Michel Guillon

J Pharmacol Toxicol Methods· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Pharmacology Evaluation of Biopharmaceuticals.
Hamid R Amouzadeh, Michael J Engwall, Hugo M Vargas

Handb Exp Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
Hugo M Vargas, Hamid R Amouzadeh, Michael J Engwall

Expert Opin Drug Saf· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of casein kinase I epsilon/delta produces phase shifts in the circadian rhythms of Cynomolgus monkeys.
Jeffrey Sprouse, Linda Reynolds, Terri A Swanson, Michael Engwall

Psychopharmacology (Berl)· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ILSI-HESI cardiovascular safety subcommittee dataset: an analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc).
Alan Y Chiang, Alan S Bass, Murray M Cooper, Michael J Engwall, Ronald G Menton

J Pharmacol Toxicol Methods· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Xian Chen, Jessica D Cass, Jenifer A Bradley, Corinn M Dahm, Zhuoqian Sun, Michael J Engwall

Br J Pharmacol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis